Nome Químico: (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-12,13-dihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3-(hydroxymethyl)-7-methoxy-5,7,9,11,13-pentamethyloxacyclotetradecane-2,10-dione ;
Sinônimo: Clarithromycin F ; 2-Demethyl-2-(hydroxymethyl)-6-O-methylerythromycin A
Sorrisos: C[C@@H]([C@@H]([C@H](C(O[C@@H]1CC)=O)CO)O[C@@](O[C@@H](C)[C@@H]2O)([H])C[C@@]2(C)OC)[C@H]([C@@](C)(C[C@H](C([C@@H]([C@@H](O)[C@@]1(O)C)C)=O)C)OC)O[C@@](O[C@H](C)C[C@@H]3N(C)C)([H])[C@@H]3O
Stability indicating HPLC-ECD method for the analysis of clarithromycin in pharmaceutical dosage forms: method scaling versus re-validation
By Makoni, Pedzisai A.; Chikukwa, Mellisa T. R.; Khamanga, Sandile M. M.; Walker, Roderick B.
From Scientia Pharmaceutica (2019), 87(4), 31
Stability indicating Rp-Hplc method development and validation for the simultaneous estimation of gemcitabine and clarithromycin in bulk and pharmaceutical dosage form
By Kumar, Y. Anil; Sirisha, Y.; Harini, A. L.; Prathyusha, A.
From World Journal of Pharmaceutical Research (2018), 7(8Spec.Iss.), 1-8
Selecting optimal columns for clarithromycin impurity analysis according to the quantitative relationship of hydrophobic subtraction model
By Zhang Xia; Hu Changqin
From Journal of pharmaceutical and biomedical analysis (2017), 136, 162-169